While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.
The investment bank also initiated coverage of Agilent Technologies, Bruker, Illumina, PerkinElmer, and Waters with a Hold rating.
There were more winners than losers in the 2015 GWDN Index, but some lost big.
Their approach detects resistance to carbapenems, drugs commonly used in hospitals and in patients with infections already resistant to other antibiotics.
The program will run for two years, and Bruker said that it will repurchase its common stock from time to time in amounts and at prices that it deems appropriate.
The approach combines collection of ions via IMS with rapid quadrupole switching to enable the fragmentation of multiple simultaneously elution precursor ions.
Discounting the negative effects of divestitures and currency exchange rates, the company posted Q3 organic growth of 8 percent and beat analysts’ consensus estimates.
Overall, analyst Bryan Brokmeier said he is bullish on the space in spite of uncertainty in the general global markets.
The company posted organic revenue growth of 1 percent and beat analysts' estimate on the top and bottom lines.
The conference was relatively light on new mass spec launches, with many vendors focusing instead on more targeted applications of existing technology.
Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.
John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.
Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.
In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.